Abstract 413P
Background
The use of circulating tumor DNA (ctDNA)-based comprehensive genomic profiling (CGP) has rapidly grown and it is now considered an important supplement or alternative to tissue-based CGP. In addition to the improved sensitivity in detecting somatic variants, incorporation of advanced features such fusion detection, tumor mutation burden (TMB) and microsatellite instability (MSI) are expected to increase the utility of ctDNA-based CGP tests. However, the validation of these features are often insufficient.
Methods
The results of hybrid-capture based ctDNA CGP tests performed in a single institute, from Dec. 2022 to Jul. 2023 using TruSight Oncology 500 ctDNA assay (Illumina, CA, USA) were retrospectively reviewed. For the cases with targetable fusions reported, medical records were reviewed to identify whether targeted therapy was delivered and whether there was a response. For the cases with existing tissue-derived TMB/MSI and/or deficient mismatch repair status, the results were compared to those from ctDNA CGP. To identify the effect of tumor fraction on TMB, correlation of tissue TMB (tTMB) and blood TMB (bTMB) was analyzed before and after the stratification by maximum somatic allele fraction (MSAF), which is a surrogate for the tumor fraction.
Results
Total number of tests performed during the study period was 634 and major cancer types included non-small cell lung cancer, colon cancer, gastric cancer, etc. Fusions involving actionable drivers such as RET, ALK, and FGFR2 were identified from 19 tests (3.0%) from 17 patients. Four patients started targeted therapy based solely on ctDNA result and as a result, three showed response and one was yet to be evaluated. For ctDNA-derived MSI, adjustment in the cutoff value provided by manufacturer, based on the results from matched tissue, deemed necessary. The correlation between bTMB and tTMB was not observed (ρ=0.063, P=0.641). Instead, bTMB was affected by tumor fraction, showing higher value in specimens with higher MSAF.
Conclusions
Fusions detected from ctDNA CGP showed promising clinical utility based on the observed response to the targeted agents. Adjustments in the cutoff and correction of the effect from tumor fraction is required for ctDNA-derived TMB/MSI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract